Pre admission treatment with Beta-blockers in hypertensive patients with acute stroke and 3-month outcome-Data from a national stroke registry.
Yoav EizenbergEhud GrossmanDavid TanneSilvia KotonPublished in: Journal of clinical hypertension (Greenwich, Conn.) (2018)
The impact of beta-blockers (BB) treatment on stroke outcome is unclear. We used data from a prospective national stroke registry to assess the associations between use of BB and poor outcome 3 months after stroke. Using the National Acute Stroke Israeli (NASIS) registry, we identified 1126 patients with ischemic stroke and intracerebral hemorrhage with pre-stroke hypertension treatment, who were followed for 3-months. Functional outcome and mortality at 3-month were compared by use of BB, adjusting for demographics and clinical factors. Pre-stroke use of BB was reported by 615 (54.6%) patients. Users of BB showed higher rates of atrial fibrillation, heart disease, statin use, cancer, and severe stroke. Adjusted odds-ratios (ORs, 95% CI) for BB users compared with non-users 3 months after stroke were 0.86 (0.49-1.52) for mortality and 1.07 (0.76-1.50) for Barthel Index ≤60. In conclusion, treatment with BB is not associated with 3-month poor outcome in hypertensive patients.
Keyphrases
- atrial fibrillation
- growth factor
- blood pressure
- hypertensive patients
- heart failure
- oral anticoagulants
- catheter ablation
- left atrial
- coronary artery disease
- cardiovascular disease
- recombinant human
- newly diagnosed
- machine learning
- risk factors
- left ventricular
- electronic health record
- deep learning
- replacement therapy
- cerebral ischemia
- direct oral anticoagulants
- blood brain barrier
- papillary thyroid
- patient reported
- childhood cancer
- arterial hypertension